Replimune Appoints Dieter K. Weinand to Board of Directors

– Woburn, MA, June 22 2018

Replimune Appoints Dr. Hyam I. Levitsky To Board Of Directors

– Woburn, MA, June 11 2018

Replimune Announces First Patients Dosed In A Phase 1/2 Clinical Trial Of Its RP1 Oncolytic Immunotherapy In Patients With Advanced Solid Tumors

– Woburn, MA, November 14, 2017

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs.

– Woburn, MA, September 8, 2017

Replimune Appoints Howard L. Kaufman, M.D., FACS as Chief Medical Officer

– Woburn, MA, September 8, 2017

Founder and CEO of Replimune Limited Honored with the IPO Education Foundation’s 43rd Annual Inventor of the Year Award

– Woburn, MA, Oxford, UK, December 7, 2016

Replimune expands its management team and moves into dedicated development facilities

– Oxford, UK, April 1st, 2016

Replimune Ltd raises $30 million Series A Financing

– OXFORD, United Kingdom. – Sept 24th, 2015

Media &

Oncolytic immunotherapy: An emerging new modality for the treatment of cancer

– May 2016

Infectious Enthusiasm

– February 29th 2016

Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.

– February 2016